Abstract-The prevalence of deficient plasma folate status and elevated total plasma levels of homocysteine (tHcy), have been dramatically reduced after fortification of all enriched cereal grain flour products with folic acid at 140 g/100 g flour. Against this new background fortification, we evaluated the tHcy-lowering efficacy of pharmacological dose, folic acid-based vitamin B supplementation among stable coronary artery disease (CAD) patients. Using a 2ϫ2 factorial design, 131 stable CAD patients (mean age 60.1 years; 29.8% women) were randomly assigned to receive a combination of folic acid 2. 
T he prevalence of both deficient plasma folate status, [1] [2] [3] [4] [5] and elevated fasting total plasma levels of the putatively atherothrombotic 6 sulfur amino acid homocysteine (tHcy), 1, 4, 5 have been dramatically reduced since the recent advent of United States 7 and Canadian 8 initiatives to fortify all enriched cereal grain flour products with physiological amounts (ie, 140 g/100 g flour) of folic acid. Presently, there are three large, randomized, controlled trials of tHcy-lowering for the potential reduction of arteriosclerotic cardiovascular disease outcomes ongoing in the United States and Canada. 9 The considerable (nutritional) biochemical effects [1] [2] [3] [4] [5] of cereal grain flour fortification with folic acid could substantially reduce the statistical power of these ongoing cardiovascular disease prevention studies. All three trials assume the patient groups assigned to active treatment will achieve the same mean tHcy-lowering treatment effects (ie, a mean reductions of Ϸ33%, or 4 to 6 mo/L) previously reported 10 in the absence of the large potential background effect of folic acid-fortified cereal grain flour. We re-examined this assumption by evaluating the tHcy-lowering efficacy of pharmacological dose, folic acid-based vitamin B supplementation among stable coronary artery disease (CAD) patients chronically exposed to cereal grain flour products fortified with folic acid at 140 g/100 g flour.
Methods
The institutional review board at Memorial Hospital of Rhode Island (Pawtucket, RI) approved the study protocol, and all participants provided written, informed consent. Study participants were 267 stable CAD patients (ie, they were at least 3 months post-myocardial infarction or coronary angioplasty and/or at least 6 months post-coronary artery bypass graft surgery). CAD status was confirmed by established 12-lead electrocardiographic and cardiac isoenzyme (ie, creatine phosphokinase MB) criteria for definite myocardial infarction, and/or unstable angina with angiographically proven Ն50% stenosis of at least one major epicardial coronary artery. Participants lived in the Pawtucket and Providence, RI, metropolitan areas and underwent their baseline examinations between October 1997, and May 1999. 5 Information regarding previous vitamin supplement use was obtained by standardized interview, and subjects were either nonusers of any supplements containing folic acid, or they had abstained from using such supplements for at least 6 weeks by the time of their examination. However, all participants were examined at least three to four months after the widespread availability in New England (John Watson, President, Watson Foods, New Haven, Conn, written communication, 1997) of cereal grain flour products fortified with folic acid at 140 g per 100 g flour. 1 Of these 267 persons examined, 131 were enrolled into the 12-week tHcy-lowering treatment phase of the study protocol based on the following criteria: a serum creatinine of 1.9 mg/dL or less; a 2-hour post-methionine load increase above their fasting tHcy levels of at least 12 mol/L; absence of clinical liver or thyroid disease, seizure disorder, uncontrolled diabetes, progressive congestive heart failure, malignancy, or cachectic disorders; chronic, stable dosing (ie, 3-months before screening and throughout the 12-week treatment phase) of medications with a potential impact [11] [12] [13] [14] [15] [16] [17] [18] on tHcy levels (ie, nicotinic acid at 1.5 g/d or moreϮcolestipol at 20 g/d or more; fenofibrate or gemfibrozil; thiazide or loop diuretics; the antiepileptic drugs carbamazepine, phenytoin, valproate, phenobarbital, or primidone; levodopa; estrogen replacement therapy, raloxifene, or tamoxifen); a willingness to participate. These 131 subjects were randomly assigned in blocks based on sex, 2-hour post-methionine load increase in tHcy levels, and fasting tHcy levels to one of four treatment groups: (I) folic acid 2. . Treatment assignments were made by a pharmacist who was blinded to all other aspects of the study. Laboratory analyses, data entry, and data analyses were performed by code so that treatment assignments remained concealed. Compliance with treatment was assessed by pill counts and determination of the change in plasma vitamin status.
Overnight (10 to 14 hours) fasting, as well as 2-hour postmethionine loading (100 mg L-methionine/kg body weight, per Bostom et al 19 ) blood samples were collected from each participant, at the screening examination, on the day of enrollment into the treatment phase, and twice during the 12th week of treatment. All whole blood specimens for tHcy and vitamin B assays were collected and stored on wet ice until the plasma was separated in a refrigerated centrifuge within 2-hours of collection, aliquoted, and stored at Ϫ70°C until analyzed. Whole blood for serum was allowed to clot at room temperature for 15 to 20 minutes, followed by prompt separation of the serum, aliquoting, and storage at Ϫ70°C until analyzed. Plasma tHcy levels were determined by using high-performance liquid chromatography with fluorescence detection, 20 and plasma pyridoxal 5Ј-phosphate levels were measured by using radioenzymatic (tyrosine decarboxylase) assay. 21 Plasma folate and vitamin B 12 levels were measured by radioassay (BioRad Quantaphase II). Serum creatinine (Jaffe method) and albumin (bromcresol method) levels were determined by using standard techniques adapted for automated clinical chemistry laboratory analyzers. To eliminate inter-assay variability, all analytes were batch assayed from thawed aliquots (cryopreserved at Ϫ70°C) obtained during each of the four study visits. All laboratory analyte values reported are based on averages of two pretreatment and post-treatment values. Descriptive statistics included arithmetic or geometric means and frequencies (percentages). Baseline continuous variables were compared by using ANOVA, and categorical variables were compared by using 2 analysis. Continuous variables were assessed by using both untransformed and (natural log) transformed values. Treatment effects on percentage changes in fasting and the 2-hour postmethionine load increase in tHcy levels were presented as average pretreatment levelϪaverage posttreatment level and were compared by using general linear modeling with ANCOVA. To assess the relative independent effects of the treatments, the ANCOVA adjusted for age, pretreatment levels of fasting or the 2-hour postmethionine load increase in tHcy, and pretreatment albumin. Table 1 reveals that randomization with respect to No B 6 (groups II and IV combined, nϭ68), Any B 6 (groups I and III combined, nϭ63), No Folic Acid (groups III and IV combined, nϭ66), and Any Folic Acid (groups I and II combined, nϭ65) was successful for the key baseline characteristics of fasting and 2-hour post-methionine load increase in tHcy levels, in addition to plasma folate, vitamin B 12 , and pyridoxal 5Ј-phosphate levels. As displayed in Table 2 , none of the treatments produced a statistically significant reduction in the 2-hour post-methionine load increase in tHcy levels, relative to placebo treatment. Finally, ANCOVA adjusted for age, as well as pretreatment fasting tHcy and albumin levels, revealed only very modest (Ϸ1.0 mol/L), albeit statistically significant (PϽ0.05), reductions in mean fasting tHcy levels afforded by the folic acid containing treatments.
Results

Discussion
We found that none of the treatments, including the vitamin B 6 -containing treatments, provided a statistically significant reduction in the 2-hour post-methionine load increase in tHcy levels, relative to placebo treatment. These data contrast with uncontrolled reports, [22] [23] [24] and our earlier randomized, placebo-controlled 2ϫ2 factorial study in renal transplant recipients, 25 demonstrating that vitamin B 6 treatment could significantly reduce mean post-methionine load increases in tHcy levels. However, in all these previous reports, [22] [23] [24] [25] subjects had lower mean plasma pyridoxal 5Ј-phosphate status, and/or significantly greater mean post-methionine load increases in their tHcy levels, at baseline. In conjunction with the current null findings, the aggregate data [22] [23] [24] [25] suggest that vitamin B 6 treatment for the potential reduction of postmethionine load tHcy levels may only be effective when vitamin B 6 status is marginal, emphasizing the role of vitamin B 6 as a cofactor, not a substrate, for cystathionine beta synthase in the transsulfuration pathway. 26 Including the current report, two controlled total homocysteine-lowering treatment studies have been completed in the United States and Canada among coronary artery disease (CAD) patient populations chronically exposed to a background of folic acid fortified cereal grain flour. Earlier, Title and colleagues 27 studied 75 stable Canadian CAD patients selected to have a fasting tHcy level Ն9 mol/L from among 166 consecutive CAD patients (ie, Ϸ50% of the total number of CAD patients screened had total homocysteine levels Ͻ9 mol/L). Subjects were randomly assigned to one of three groups of 25 patients each, receiving 5 mg/d folic acid, with or without 2 g/d vitamin C and 800 IU/d vitamin E (ie, 50 patients received 5 mg/d folic acid), or placebo, for 16 weeks of treatment. For the 50 patients receiving 5 mg/d folic acid, mean fasting tHcy levels were 12.1 mol/L pretreatment and 10.9 mol/L post-treatment, a Ϫ1.2 mol/L difference. For the 25 patients receiving placebo, mean fasting tHcy levels were 12.1 mol/L pretreatment and 11.8 mol/L post-treatment, a Ϫ0.3 mol/L difference. Preliminary data consistent with the findings of Title and colleagues 27 have been presented by the PACIFIC trial investigators 28 in CAD patients unexposed to mandated flour fortification with folic acid, but with comparable baseline plasma folate status. These investigators have reported that folic acid at doses of 0.2 mg/d and 2.0 mg/d for 6 months reduced mean fasting tHcy levels by only 1.2 or 1.7 mol/L, respectively, relative to placebo among 723 individuals with stable CAD. 24 Our trial further demonstrated that only very modest reductions in mean fasting tHcy levels were achieved even when CAD patients received supraphysiological doses of folic acid, combined with high doses of vitamin B 12 , vitamin B 6 , and riboflavin.
The findings of Title and colleagues 27 are directly relevant to the screening strategy of the Vitamin Intervention for Stroke Prevention (VISP) investigators, 29 whereas our current data are directly relevant to the designs of the Heart Outcomes Prevention Evaluation (HOPE-2) and Women's Antioxidant Cardiovascular Disease Study (WACS) trials, 9 both of which do not include any screening tHcy level eligibility criteria. The rather meager reductions in mean fasting tHcy levels (ie, approximately Ϫ1 mo/L) achieved in the two CAD populations studied were well below the assumed tHcy-lowering treatment effect of a mean reduction of Ϸ4 to 6 mo/L. 9,10 The data we have presented highlight the impact of flour fortification with folic acid in patients with established cardiovascular disease, who are free of overt chronic renal disease, ie, a tHcy-lowering treatment responsiveness to high-dose folic acid-based regimens that results in only very modest reductions in their mean tHcy levels. As a consequence, the three ongoing United States and Canadian clinical trials attempting to evaluate the hypothesis that tHcylowering treatment will reduce arteriosclerotic cardiovascular disease outcomes (VISP, HOPE-2, and WACS), will likely achieve only Ϸ20% to 25% (ie, mean reductions of 1.0 to 1.5, versus 4.0 to 6.0 mol/L) of their projected mean tHcylowering treatment effects. Accordingly, none of these trials would remain adequately powered to test their specific total homocysteine-lowering hypotheses identified a priori. 
